Single-Dose, Dose-Escalation Study With LY3303560 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Subjects and Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease

Trial Profile

Single-Dose, Dose-Escalation Study With LY3303560 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Subjects and Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Sep 2017

At a glance

  • Drugs LY 3303560 (Primary) ; LY 3303560 (Primary)
  • Indications Alzheimer's disease; Cognition disorders
  • Focus Adverse reactions; First in man
  • Sponsors Eli Lilly
  • Most Recent Events

    • 31 Aug 2017 Planned End Date changed from 1 May 2019 to 1 Apr 2018.
    • 31 Aug 2017 Planned primary completion date changed from 1 May 2019 to 1 Apr 2018.
    • 02 Aug 2017 Planned number of patients changed from 90 to 110.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top